Drawing on extensive leadership experience in pharmaceutical packaging and his recent work through Red Zenith, Nadir Lahmeur shares three observations shaped by conversations across the pharmaceutical packaging ecosystem with pharmaceutical companies, CDMOs, packaging manufacturers, technology developers, and investors.
When Nadir Lahmeur launched Red Zenith, he expected to spend most of his time helping companies across the pharmaceutical packaging ecosystem expand their business, refine their packaging strategies, and build the right partnerships. What he didn’t expect was how much it would broaden his own perspective on the industry.
For most of his career, Nadir Lahmeur viewed the market through the lens of the organization he was working for. More recently, his work has brought him into conversations with a broader range of pharmaceutical companies, CDMOs, compounders, packaging manufacturers, medical device developers, inventors, regulatory experts, and investors. Those conversations have provided a much broader perspective on the pharmaceutical packaging ecosystem than he had experienced previously.
Perhaps most striking has been how often the same themes emerge. Regardless of the product, technology, or market segment, organizations across the industry are often facing remarkably similar challenges while pursuing many of the same opportunities.
The observations that follow are not intended to be predictions or a comprehensive assessment of the industry. Rather, they reflect recurring themes that have consistently emerged from conversations across the pharmaceutical packaging ecosystem over the past year.
Observation 1: Great Ideas Are Only the Beginning
One theme has consistently emerged from his discussions over the past year: innovation is certainly not lacking in the industry.
Whether speaking with pharmaceutical companies, component manufacturers, medical device developers, inventors, or entrepreneurs, he has been impressed by the number of creative ideas and promising technologies being developed. In many cases, the technical solution itself is not the limiting factor.
The real challenge often begins after the innovation.
How do you scale manufacturing while maintaining quality? How do you navigate increasingly complex regulatory requirements? How do you secure the funding needed to move from development to commercialization? How do you scale in a way that remains economically viable? How do you identify the right commercial partners and successfully bring a product to market?
These questions require a different set of capabilities than innovation alone.
Based on the conversations he has had over the past year, one pattern continues to emerge: successful innovation is rarely the result of one company doing everything well. More often, it comes from organizations that understand their strengths, recognize where they need complementary expertise, and build the right partnerships to transform an idea into a successful business.
Observation 2: No Company Can Do It Alone
One of the biggest changes he has observed over the past year is how specialized the industry has become.
Not long ago, many companies aspired to provide complete solutions within their own organizations. Today, the pace of innovation, increasing regulatory expectations, and the growing complexity of pharmaceutical products have made it nearly impossible for one company to excel in every area.
Instead, companies are becoming exceptionally good at what they do best.
Some specialize in primary packaging. Others focus on medical devices, drug delivery systems, elastomer components, contract manufacturing, automation, regulatory support, or commercialization. Individually, these capabilities are impressive. The challenge is combining the right expertise to efficiently move an innovation from concept to commercialization.
Regardless of where they sit in the value chain, most organizations are pursuing the same objective: sustainable growth. The path to achieving that growth, however, increasingly depends on capabilities that often lie outside their own organization.
The rapid growth of GLP-1 therapies is a good example. The challenge extended well beyond developing an effective drug. Manufacturers had to rapidly expand production, secure delivery devices, increase fill-finish capacity, and scale final packaging, all while maintaining quality and regulatory compliance. No single organization could realistically solve every part of that challenge alone. Pharmaceutical companies, CDMOs, packaging specialists, device manufacturers, and logistics providers each played an essential role in building the capacity needed to meet unprecedented demand.
This is a pattern that continues to emerge across many areas of the pharmaceutical packaging industry. The technology often exists. The expertise exists. The market opportunity exists. What is frequently missing is the connection between them.
Increasingly, competitive advantage is no longer created by one company working in isolation, but by organizations that recognize where complementary capabilities exist and bring them together. In an industry where specialization continues to increase, choosing the right partners may become just as important as choosing the right technology.
Observation 3: The Broader the Perspective, the Better the Decisions
Perhaps the most important observation is that the best decisions are rarely made by looking at one part of the value chain in isolation.
Whether discussing a new therapy, a delivery device, a packaging system, or a manufacturing process, each decision influences the next. Understanding those interdependencies often reveals opportunities that would otherwise be missed.
This applies equally to pharmaceutical companies, technology developers, packaging manufacturers, CDMOs, and investors. Regardless of where an organization sits within the ecosystem, success begins with understanding where it creates value, how that value complements others, and what problems it is uniquely positioned to solve.
One pattern that continues to emerge is that organizations sometimes become deeply invested in their own solution before fully validating the problem they are trying to solve. The most successful organizations tend to take the opposite approach. They spend time understanding the market, listening to customers, seeking input from key opinion leaders, and challenging their own assumptions before committing to a strategy.
In a highly specialized industry, technical excellence remains essential. But technical excellence alone rarely guarantees commercial success. The organizations that consistently make better decisions are often those that combine deep expertise with a broad understanding of the ecosystem in which they operate.
Conclusion
The pharmaceutical packaging industry has never been more dynamic. New therapies, technologies, and business models continue to expand the possibilities for improving patient care.
At the same time, success is becoming less about mastering a single discipline and more about understanding how the different parts of the industry fit together. Whether developing a new product, entering a new market, or building the next strategic partnership, the broader the perspective, the better the decisions.
Perhaps the biggest lesson is not that the pharmaceutical packaging industry has become more complicated, but that it has become more connected. Organizations that understand those connections will be better equipped to identify opportunities, build meaningful partnerships, and make better strategic decisions.
